Could a diabetes drug shield Kids' kidneys? new trial launches

NCT ID NCT06430684

Recruiting now Disease control Sponsor: Ann & Robert H Lurie Children's Hospital of Chicago Source: ClinicalTrials.gov ↗

First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This early-phase trial aims to see if it's possible to run a study of empagliflozin, a drug already used in adults for kidney disease, in 40 children with chronic kidney disease. Participants are randomly assigned to take the drug or continue usual care for 3 months. Researchers will check if the drug is safe and if it improves blood pressure, urine markers, and heart function.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: Empagliflozin (a diabetes drug that may protect kidneys and heart)
What this could lead to: If successful, this could pave the way for larger trials testing whether empagliflozin helps slow kidney disease in children.
What could go wrong: This is a very early, small feasibility study with only 40 participants and 3 months of treatment. It is not designed to prove effectiveness, and results may not apply to all children with kidney disease.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for CHRONIC KIDNEY DISEASES are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

chronic kidney disease chronic renal failure syndrome kidney disorder

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

CHRONIC KIDNEY DISEASES PEDIATRIC KIDNEY DISEASE

Contacts and locations

Locations

Ann & Robert H. Lurie Children's Hospital of Chicago
RECRUITING

Chicago, Illinois, 60611, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.